| Similar Articles |
|---|
 |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.   |
The Motley Fool
September 28, 2009
Brian Orelli |
The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies. |
The Motley Fool
January 24, 2006
Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
January 26, 2005
Rich Smith |
J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies. |
Pharmaceutical Executive
May 1, 2009 |
Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration. |
Pharmaceutical Executive
September 1, 2005
Bill Trombetta |
2005 Industry Audit Who's really on top in the pharmaceutical industry? |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
Pharmaceutical Executive
July 3, 2007 |
Direct to Consumer: The Secret of My Success Pharmaceutical industry experts sound off on the methods behind an award-winning ad and how the next great direct-to-consumer campaign will come about. |
CRM
August 21, 2015 |
Instantly Partners with Viggle Integration of Instantly into Viggle app will increase users' opportunities to earn rewards while enhancing Instantly's measurement of mobile ad effectiveness. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool
June 16, 2005
Stephen D. Simpson |
Media Drug Withdrawal? Are pharmaceutical companies turning away from mass marketing through TV? |
The Motley Fool
May 12, 2010
Nick Kapur |
J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video. |
The Motley Fool
August 24, 2010
Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? |
The Motley Fool
March 20, 2009
Brian Orelli |
No More Tears, Far More Fears? China's Food and Drug Administration said that it's investigating products made by our beloved Johnson & Johnson, after a U.S. group reported that there may be carcinogens in J&J's baby shampoo. |
U.S. Banker
February 2002
David Lo |
Escape the Knife Bank marketers are spending as much -- or more -- than ever on retail ads despite an economy that's in the dumps... |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
BusinessWeek
June 7, 2004
Gene G. Marcial |
St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors. |
The Motley Fool
November 29, 2007
Anders Bylund |
Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson. |
The Motley Fool
May 23, 2007
Brian Orelli |
Pharma TV -- All Drugs, All the Time A combined media effort of four big pharmas in Europe sounds like a great idea, from an investor's perspective. But will it work? |
Pharmaceutical Executive
September 1, 2006
Bill Trombetta |
Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers. |
InternetNews
November 13, 2007
Kenneth Corbin |
It's Not Your Father's Ad Industry IBM study predicts the rise of interactive advertising to stand the industry on its head. |
The Motley Fool
November 9, 2006
Tom Taulli |
LookSmart Looking Like a Growth Company Is a strong third quarter at the online advertising company the beginning of sustainable growth? Investors, take note. |
The Motley Fool
October 22, 2010
Anand Chokkavelu |
7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential. |
The Motley Fool
September 11, 2010
Anand Chokkavelu |
How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis. |
InternetNews
August 17, 2006
David Needle |
What's in a Tech Name? Dell's massive recall of some 4.1 million notebook batteries is more than just a costly technical blunder. It also risks losing the company years of brand equity. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
October 30, 2010
Anand Chokkavelu |
7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk... |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks. |
InternetNews
April 23, 2004
Robyn Greenspan |
Consumers Becoming Marketing-Resistant A worsening attitude toward marketing messages presents new challenges for advertisers, as consumers are willing to accept extreme solutions. |
The Motley Fool
December 31, 2007
Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. |
The Motley Fool
December 6, 2007
Brian Orelli |
An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off? |
The Motley Fool
August 3, 2005
Steven Mallas |
JNJ: One to Monitor Johnson & Johnson might not exactly be a bargain, but it should always be on your stock watch list. |
The Motley Fool
May 2, 2011
Anupama Pattanaik |
J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion. |
InternetNews
July 26, 2007
Nicholas Carlson |
Microsoft Adds Its Own Ad Exchange Microsoft announced it bought advertising exchange platform company AdECN, adding to its growing portfolio of online advertising businesses. |
The Motley Fool
January 12, 2006
Stephen D. Simpson |
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note. |
BusinessWeek
August 15, 2005
Barrett & Weintraub |
Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages. |
BusinessWeek
October 10, 2005 |
J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows. |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years. |
The Motley Fool
November 15, 2005
Stephen D. Simpson |
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note. |
Fast Company
April 2002
Christine Canabou |
Advertising, Under Review Someone unplugged the entire ad business. When it comes to spending -- whether the medium is television, print, or the Internet -- the boom times are over. Six advertising insiders take the industry to account... |
Search Engine Watch
January 17, 2005
Greg Jarboe |
Online Ads & Search: Looking Back, Looking Forward Paid search led the resurgence of online advertising in 2004 with a 34% increase in growth, and this trend is expected to continue over the coming five years. |
InternetNews
May 18, 2007
Clint Boulton |
Online Ad Pockets Grow in Microsoft's $6B Buy Microsoft today agreed to acquire online advertising company aQuantive for $6 billion in cash, a move that will help the software giant carve out some serious territory in the online advertising battleground. |
The Motley Fool
December 5, 2005
Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
CRM
May 2012
Judith Aquino |
Marketing and Advertising Agencies Blur the Lines Third-party partners are broadening their roles. What to consider for the perfect pairing. |
